Recap: Dare Bioscience Q3 Earnings

Shares of Dare Bioscience DARE moved higher by 0.9% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 20.00% year over year to ($0.24), which missed the estimate of ($0.17).

Revenue of $0 unchanged by 0.00% year over year, which missed the estimate of $180,000.

Looking Ahead

Dare Bioscience hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 12, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/2gycp6iy

Technicals

52-week high: $2.22

Company's 52-week low was at $0.69

Price action over last quarter: down 5.13%

Company Profile

Dare Bioscience Inc is a clinical-stage biopharmaceutical company focused on women's reproductive health. The products of the company are related to fertility, vaginal health, and contraception. Ovaprene is a product designed by the company to provide multiple weeks of contraceptive protection without the use of hormones.